A woman's story of literal strength shows how ovarian cancer can be missed—and the lighthearted recovery milestone every care ...

A new case report was published in Oncoscience's Volume 12 on March 31, 2025, titled "Cystadenofibroma and contralateral collision lesions: A unique ovarian case report." ...

A new drug tested in a phase 3 trial showed significant improvement in patients with treatment-resistant ovarian cancer.

In a study co-led by the University of Maryland School of Medicine (UMSOM), researchers have identified a "master regulator" ...

"They are also more likely to die of their disease." Diagnosing ovarian cancer earlier improves chances of survival. "The ...

University of Kentucky Markey Cancer Center researchers presented promising results from an early-stage clinical trial ...

A standard diagnostic test for ovarian cancer is less effective in detecting the disease among Black and Native American ...

Results from a new Phase 3 trial published in the journal npj Precision Oncology found that an assay that includes an ...

A phase 3 trial of nemvaleukin alfa in with Keytruda for patients with platinum-resistant ovarian cancer will not continue on ...

A common blood test may miss ovarian cancer in some Black and Native American patients, delaying their treatment, a new study ...

The first patient was dosed in a phase 3 trial of IBI354 for platinum-resistant ovarian cancer with HER2 expression.

In a study co-led by the University of Maryland School of Medicine (UMSOM), researchers have identified a “master regulator” ...